A 160% spike tells the story of India-Iceland pharmaceutical trade

The Trade and Economic Partnership Agreement (TEPA) between Iceland and India entered force on 1 October 2025, and the numbers tell quite a story. $1.3 million worth of other heterocyclic nitrogen compounds landed in Reykjavik from India in 2025 — that's a 160% surge from last year's $511,240.

That puts India squarely in second place with a 39% share of Iceland's $3.4 million market for these specialized pharmaceutical building blocks. The UK still leads with 50%, but Indian exporters, particularly those in the organic chemicals, pharmaceuticals, and food processing industries, are targeting the EFTA and Swiss markets under the newly operational trade deal.

The Chemical Factory Next Door

The pharmaceutical giants are all here. Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Divi's Laboratories together control nearly 60% of India's pharmaceutical exports. Sun Pharmaceutical Industries exports the most, with over $4.8 billion in annual exports in 2024, Dr. Reddy's follows with $2.1 billion, Cipla with $2.5 billion, and Divi's with $1.2 billion in API exports.

"India-EFTA TEPA is an agreement with a long-term economic purpose. It gives Indian exporters access to high-income markets, creates an investment pathway of USD 100 billion over 15 years."

These aren't just big pharma operations — they're precision chemistry. Over 200 global companies, including Pfizer and Novartis, rely on Divi's for APIs. Dr. Reddy's produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture. These specialty heterocyclics don't fit the standard categories — think custom molecules for specific therapeutic applications.

From Gujarat Mills to Nordic Labs

The supply chain starts in India's pharmaceutical heartland. Ahmedabad GIDC in Gujarat houses the bulk chemical producers. Genome Valley in Hyderabad is where the biotech meets big pharma. Up in Baddi, Himachal Pradesh, the mountain air keeps costs down for API manufacturing.

CHEMEXCIL was established by the Ministry of Commerce & Industry Government of India in the year 1963 with the objective of promoting exports from India to various abroad countries. The Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council represents over 4,000 members today.

These heterocyclic compounds end up in Iceland's small but lucrative pharmaceutical market. With 380,000 people and one of the world's highest per-capita healthcare spends, Iceland represents quality over quantity. The compounds likely feed into generic drug manufacturing or research applications at Iceland's biotech sector.

Jobs and Livelihoods: The MSME Story

Here's where the math gets interesting. Based on India's pharmaceutical sector employment patterns, this $1.3 million trade flow supports an estimated 46 direct jobs (using the 3.5 per $100,000 multiplier for pharmaceuticals) and 119 indirect positions in packaging, logistics, and support services.

The real employment impact sits with India's MSMEs. An estimated 80% of this trade flows through small and medium enterprises, many of them family-owned chemical trading houses. About 30% of workers in this segment are women, often in quality control, packaging, and administrative roles.

India's pharmaceutical exports have witnessed a remarkable ascent, surging by over 9 percent between April and February of the fiscal year 2023-24, with exports to the United States exhibiting robust growth, soaring by over 15 percent during the same period. Iceland may be a smaller market, but it's part of a broader European expansion.

"The Agreement strengthens India's export presence in high purchasing power markets securing binding commitments across pharmaceuticals, textiles and garments, engineering goods, chemicals, processed foods and marine products."

Looking ahead, the competitive landscape shows India gaining ground. Switzerland holds third place with $339,461, Germany fourth with $36,520. China, despite its manufacturing scale, managed just $5,468 — a reminder that specialty chemicals favor expertise over volume.

The agreement incorporates commitments on sustainable development and includes an unprecedented investment pledge of $100 billion from the EFTA side to India over 15 years. For Iceland specifically, this pharmaceutical trade represents early evidence that after 16 years of intermittent negotiations, the TEPA framework is delivering results.